Paliperidone: 6 agencies, 2007–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 15.8 years separate the first record, 24 Sep 2007 at ZIN (Netherlands), from the most recent, 21 Jun 2023 at HAS (France).
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for paliperidone, 1 submission was never made — an outcome set by the company rather than the assessor.
The programme is broad: 9 distinct indication wordings are recorded for paliperidone by the agencies that label one in English (AWMSG and SMC).
ZIN (Netherlands) was first to assess paliperidone, on 24 Sep 2007; HAS (France) did not open a file until 1 Feb 2012 — a wide spread of 4.4 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 9 years in total.
5 of the 6 agencies here assessed paliperidone more than once, AWMSG (Wales) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for paliperidone.
The full ledger for paliperidone reads 9 recommended, 4 not recommended, 2 not assessed and 1 other, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Jun 2023 | Re-assessment following post-listing study results | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 13 Jul 2022 | Maintenance treatment of schizophrenia in adult patients who are clinically stable on 1‑monthly or 3‑monthly paliperidon… | outside AWMSG criteria | source |
| PHARMAC (New Zealand) | 17 May 2022 | Schizophrenia | PTAC advice: High · decision reached | source |
| SMC (Scotland) | 7 Nov 2011 | For maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous respo… | unknown | source |
| TLV (Sweden) | 23 Oct 2008 | Invega får avslag | rejection or exclusion | source |
13 further decisions for paliperidone, across 6 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- aripiprazole — same ATC class N05A — Psycholeptics
- risperidone — same ATC class N05A — Psycholeptics
- olanzapine — same ATC class N05A — Psycholeptics
- quetiapine — same ATC class N05A — Psycholeptics
- lurasidone — same ATC class N05A — Psycholeptics
- droperidol — same ATC class N05A — Psycholeptics
Coverage: 18 decisions for paliperidone from 6 agencies, 2007 to 2023. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.